BRAF mutations have been identified as targetable, oncogenic mutations in many cancers.
Given the paucity of treatments for primary brain tumors and the poor prognosis associated …

One of the most lethal and aggressive types of malignancies with a high mortality rate and
poor response to treatment is glioblastoma multiforme (GBM). This means that modernizing …

Combination therapies have become a standard for the treatment for HIV and hepatitis C
virus (HCV) infections. They are advantageous over monotherapies due to better efficacy …

Intramedullary spinal cord tumors (IMSCTs) comprise a rare subset of central nervous
system (CNS) tumors that can develop at any age and have distinct management strategies …

OBJECTIVE Pediatric low-grade gliomas (pLGGs) frequently exhibit dysregulation of the
mitogen-activated protein kinase (MAPK) pathway. Targeted therapies, including mutant …

Background: Diffuse intrinsic pontine glioma (DIPG) is a fatal disease with a median overall
survival (OS) of less than 12 months after diagnosis. Radiotherapy (RT) still remains the …

Background: Although low-grade glioma (LGG) has a good prognosis, it is prone to
malignant transformation into high-grade glioma. It has been confirmed that the …

In the past decade significant advancements have been made in the discovery of targetable
lesions in pediatric low-grade gliomas (pLGGs). These tumors account for 30-50% of all …

Immune signal transduction is crucial to the body's defense against viral infection.
Recognition of pathogen-associated molecular patterns by pattern recognition receptors …

Introduction BRAF V600 E mutations have been identified in a subset of patients with
primary brain tumors. Combination therapy with BRAF and Mitogen-activated protein kinase …